PegFilgrast
Rx6 mg/0.6 ml • SC Injection
Indications & Uses
PegFilgrast is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
The recommended dosage of Pegfilgrastim is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle in adults. Do not administer Pegfilgrastim between 14 days before and 24 hours after administration of cytotoxic chemotherapy. Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Pegfilgrastim if discoloration or particulates are observed.NOTE: The needle cover on the single-use pre-filled syringe contains dry natural rubber (latex); persons with latex allergies should not administer this product.
Side Effects
Splenic Rupture: Splenic rupture, including fatal cases, can occur following the administration of PegNeufil. Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain after receiving PegNeufil.Acute Respiratory Distress Syndrome: Acute Respiratory Distress Syndrome (ARDS) can occur in patients receiving PegNeufil. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving PegNeufil for ARDS. Discontinue PegNeufil in patients with ARDS.Serious Allergic Reactions: Serious allergic reactions, including anaphylaxis can occur in patients receiving PegNeufil. The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue PegNeufil in patients: with serious allergic reactions. Do not administer PegNeufil to patients with a history of serious allergic reactions to PegNeufil or Filgrastim. Patients with Sickle Cell Disorders: Severe sickle cell crises can occur in patients with sickle cell disorders receiving PegNeufil. Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disorders receiving Filgrastim, the parent compound of PegNeufil.
Cautions & Contraindications
Warnings & Precautions
Fatal splenic rupture can occur. Evaluate for splenomegaly or splenic rupture in patients with left upper abdominal or shoulder pain. Acute Respiratory Distress Syndrome (ARDS) can occur. Evaluate for ARDS in patients who develop fever, lung infiltrates, or respiratory distress. Discontinue PegNeufil in patients with ARDS. Serious allergic reactions, including anaphylaxis, can occur. Permanently discontinue PegNeufil in patients with serious allergic reactions.
Contraindications
Do not administer Pegfilgrastim to patients with a history of serious allergic reactions to pegfilgrastim or filgrastim.